Peptide Receptor Radionuclide Therapy administered to Participants withMeningioma with 67Cu-SARTATE: A single-centre, open-label, nonrandomised,Phase I-IIa Theranostic Clinical Trial
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs 64Cu-MeCOSar-Octreotate (Primary) ; 67Cu-MeCOSar-Octreotate-Clarity-Pharmaceuticals (Primary)
- Indications Meningioma
- Focus Adverse reactions
- Sponsors Clarity Pharmaceuticals
- 08 Aug 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.
- 01 Mar 2018 Status changed from planning to not yet recruiting.